Filing Details

Accession Number:
0001209191-21-042857
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-23 20:26:27
Reporting Period:
2021-06-21
Accepted Time:
2021-06-23 20:26:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1733294 Generation Bio Co. GBIO Pharmaceutical Preparations (2834) 814301281
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1742765 Atlas Venture Associates X, Llc 300 Technology Square, 8Th Floor
Cambridge MA 02139
No No Yes No
1742766 Atlas Venture Associates X, L.p. 300 Technology Square, 8Th Floor
Cambridge MA 02139
No No Yes No
1780065 Atlas Venture Associates Opportunity I, L.p. 300 Technology Square, 8Th Floor
Cambridge MA 02139
No No Yes No
1780066 Atlas Venture Associates Opportunity I, Llc 300 Technology Square, 8Th Floor
Cambridge MA 02139
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-06-21 59,978 $24.82 155,708 No 4 S Direct
Common Stock Disposition 2021-06-21 3,796 $25.12 151,912 No 4 S Direct
Common Stock Disposition 2021-06-21 111 $24.82 897 No 4 S Indirect See footnote
Common Stock Disposition 2021-06-21 7 $25.12 890 No 4 S Indirect See footnote
Common Stock Disposition 2021-06-22 33,261 $24.76 118,651 No 4 S Direct
Common Stock Disposition 2021-06-22 25,208 $25.20 93,443 No 4 S Direct
Common Stock Disposition 2021-06-22 61 $24.76 829 No 4 S Indirect See footnote
Common Stock Disposition 2021-06-22 47 $25.20 782 No 4 S Indirect See footnote
Common Stock Disposition 2021-06-23 34,162 $25.08 59,281 No 4 S Direct
Common Stock Disposition 2021-06-23 28,331 $25.69 30,950 No 4 S Direct
Common Stock Disposition 2021-06-23 63 $25.08 719 No 4 S Indirect See footnote
Common Stock Disposition 2021-06-23 53 $25.69 666 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Direct
No 4 S Direct
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Direct
No 4 S Direct
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Footnotes
  1. Shares were sold pursuant to a Rule 10b5-1 trading plan dated April 20 ,2021.
  2. The shares reported herein give effect to the pro rata distribution of shares by Atlas Venture Fund X, L.P. for no additional consideration to its limited partners and its and general partner, Atlas Venture Associates X, L.P. ("AVA X LP"), subsequent to the Reporting Persons' last Section 16 filing reporting ownership of the Issuer's Common Stock. As the distribution of such shares constituted only a change in the form of the Reporting Persons' ownership in such shares, the Reporting Persons were not required to report the distribution pursuant to Section 16.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.08 to $25.07 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (5), (8), (9), (10) and (11).
  4. The shares are held directly by AVA X LP. Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVA X LP except to the extent of its pecuniary interest therein, if any.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.08 to $25.20 inclusive.
  6. The shares reported herein give effect to the pro rata distribution of shares by Atlas Venture Opportunity Fund I, L.P. for no additional consideration to its limited partners and its and general partner, Atlas Venture Associates Opportunity I, LP ("AVAO LP"), subsequent to the Reporting Persons' last Section 16 filing reporting ownership of the Issuer's Common Stock. As the distribution of such shares constituted only a change in the form of the Reporting Persons' ownership in such shares, the Reporting Persons were not required to report the distribution pursuant to Section 16.
  7. The shares are held directly by AVAO LP. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVAO LP except to the extent of its pecuniary interest therein, if any.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.08 to $25.07 inclusive.
  9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $25.285 inclusive.
  10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.63 to $25.62 inclusive.
  11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.63 to $25.95 inclusive.